IGHS had the pleasure to welcome SanderStrothmann in Coimbra
The IGHS Group, through its subsidiary INNOV-CELL THERAPEUTICS, has been focused on the development of innovative biotechnological-based therapeutic solutions in the dermatological sector.
This week we had the pleasure to welcome in Coimbra some elements of the german multinational company SanderStrothmann GmbH, with the main goal to strengthen our commercial relationship.
Two days of intense work where were discussed new projects that resulted in the guarantee of the development of new innovative products to reinforce the Kelo.Cell product line.
Our guests had also the opportunity to visit BASI Laboratories, located in Mortágua.
Combining innovation and high quality, next year IGHS will have new products, developed by SanderStrothmann’s R&D, available on the market.
Another investment of IGHS Group focused on the overall health of the patient.
-
Innov.Cell ended its successful participation in CPHI 2024
Innov.Cell, a subsidiary of IGHS, ended its successful participation in CPHI 2024, which took place in Milan, with a positive outcome. This year, CPHI was attended by more than 62,000 people and around 2,400 exhibitors from 166 countries. Throughout the event, Innov.Cell met with several potential partners, from R&D, investors, and distributors covering more than 50 countries.
Read more -
OIH Introduces Revolutionary Treatment for Keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS)
Oman International Hospital is thrilled to announce the successful introduction of a groundbreaking procedure designed to treat keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS). This innovative treatment marks a significant advancement in ophthalmology, offering new hope to patients suffering from this debilitating corneal disorder.
Read more